US SEC Trading Suspension Halt Orders — September 02, 2026

Strategic pivot to in vivo cell therapy for solid tumors (PRAME, MAGE-A4) with 100% complete donor chimerism in 13/13 patients in Phase 1; first IND expected Q3 2027, Phase 1 initiation Q4 2027

Workforce reduction of 75% expected to generate $55M in cumulative cost savings, extending cash runway into Q4 2027, providing a 12-month operational buffer

Received Nasdaq non-compliance notice for bid price below $1.00 for 30 consecutive days; has 180-day cure period until Feb 23, 2027, with potential for a second 180-day extension via reverse stock split

Received Nasdaq deficiency notice for failing to maintain $35M MVLS; actively disputing Panel's discretionary jurisdiction through Oct 14, 2026, and evaluating judicial relief, indicating aggressive legal strategy

Received Nasdaq deficiency notice for failing to file Form 10-Q for period ended June 30, 2026; has 60 days to submit compliance plan, with possible extension until Feb 16, 2027

Quickly resolved Audit Committee non-compliance by appointing Kevin Cheong Jia Jin; Nasdaq confirmed compliance regained, no financial or operational impact

Preclinical data for solid tumor program expected in Q1 2027, providing a near-term catalyst for valuation if positive

Non-compliance does not immediately affect business operations or SEC reporting, providing a temporary buffer for operational turnaround

Paused Phase 3 ALLOHA-2 study due to insufficient capital; 75% workforce reduction signals severe cash burn and potential inability to fund all pipeline programs

Stock price below $1.00 for 30 consecutive days; if not cured by Feb 23, 2027, faces delisting, which could trigger further price decline and liquidity crisis

MVLS below $35M for 30 consecutive days; dispute with Nasdaq Panel adds legal uncertainty; failure to regain compliance could lead to delisting and loss of public market access

Failed to file Form 10-Q for Q2 2026; repeated non-compliance could lead to delisting and loss of investor confidence; no assurance of regaining compliance

Pivot to solid tumors is unproven; IND filing not expected until Q3 2027, leaving a 12-month gap with no near-term revenue or catalyst

Disputing Nasdaq Panel's discretionary jurisdiction; if judicial relief fails, could face expedited delisting process, amplifying downside

Potential reverse stock split to regain compliance could dilute existing shareholders and signal financial distress

Filing failure may indicate deeper operational or financial issues; no revenue or growth data provided to assess health

Strategic pivot to high-potential solid tumor space with promising preclinical data; 75% cost reduction extends runway; first IND in Q3 2027 could be a major catalyst if successful

Preclinical data for solid tumor program expected Q1 2027; positive results could drive significant re-rating given current distressed valuation

180-day cure period provides time for operational improvements or reverse split; if stock recovers above $1.00, delisting risk dissipates, offering potential upside

If successful in disputing Nasdaq Panel's jurisdiction, could avoid delisting; current dispute may create asymmetric upside if resolved favorably

60-day window to submit plan; if accepted, extension until Feb 16, 2027 provides time to file 10-Q and regain compliance, avoiding delisting

Quick resolution of Audit Committee vacancy demonstrates strong governance; no financial impact, making it a safe holding in a risky sector

$55M in cumulative cost savings from workforce reduction could improve cash flow metrics; if pipeline advances, could become self-funding

3 of 5 filings (IRIDEX, Triller, Reborn Coffee) received deficiency notices on the same day (Aug 27, 2026), suggesting a potential market-wide sell-off in micro-caps or a tightening of exchange enforcement; investors should monitor for broader contagion

TScan's 75% workforce reduction and paused Phase 3 study highlight ongoing capital constraints in pre-revenue biotech; companies with high cash burn and no near-term revenue face elevated delisting risk

TEN Holdings' quick governance fix contrasts sharply with financial non-compliance at IRIDEX, Triller, and Reborn Coffee; governance issues are resolvable, but financial non-compliance often signals deeper distress

Triller's active dispute of Nasdaq Panel authority introduces legal risk but also a potential path to avoid delisting; investors should watch for judicial outcomes that could set precedents for other companies

Reborn Coffee's failure to file Form 10-Q is a leading indicator of operational or financial distress; such failures often precede more severe compliance issues or bankruptcy

Solid tumor program data expected Q1 2027; positive results could be a major catalyst; watch for updates on IND filing timeline

Monitor daily closing bid price; if it remains below $1.00, watch for reverse split announcement or operational turnaround by Feb 23, 2027

Watch for judicial relief outcome regarding Nasdaq Panel jurisdiction; decision expected before Oct 14, 2026; could determine delisting fate

60-day deadline to submit plan (by late Oct 2026); watch for filing of Form 10-Q and Nasdaq response; extension until Feb 16, 2027 is possible

Monitor for additional cost-saving measures or partnership announcements; cash runway into Q4 2027 provides 12-month visibility

Watch for additional deficiency notices to other micro-cap companies; cluster on Aug 27 may signal broader trend; could impact sector sentiment

No immediate risk, but monitor for any further board changes; quick resolution suggests strong governance, but any future departures could trigger new non-compliance